|
CA2517256C
(en)
*
|
2003-02-26 |
2013-04-30 |
Sugen, Inc. |
Aminoheteroaryl compounds as protein kinase inhibitors
|
|
US20060035907A1
(en)
*
|
2004-02-23 |
2006-02-16 |
Christensen James G |
Methods of treating abnormal cell growth using c-MET and m-TOR inhibitors
|
|
EP1719762B1
(en)
|
2004-02-27 |
2012-06-27 |
Eisai R&D Management Co., Ltd. |
Novel pyridine derivative and pyrimidine derivative (1)
|
|
MXPA06010520A
(es)
*
|
2004-03-30 |
2007-03-26 |
Chiron Corp |
Derivados de tiofeno sustituidos como agentes anticancerosos.
|
|
US8008301B2
(en)
|
2004-04-01 |
2011-08-30 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
SI1735278T1
(sl)
*
|
2004-04-01 |
2010-05-31 |
Lilly Co Eli |
Agenti histamin h receptorja priprava in terapevtska uporaba
|
|
ES2534605T3
(es)
*
|
2004-08-23 |
2015-04-24 |
Eli Lilly And Company |
Agentes receptores de la histamina H3, preparación y usos terapéuticos
|
|
BRPI0514687A
(pt)
*
|
2004-08-26 |
2008-06-17 |
Pfizer |
compostos amino heteroarila como inibidores de proteìna tirosina cinase
|
|
ME01309B
(me)
*
|
2004-08-26 |
2013-12-20 |
Pfizer |
Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza
|
|
BR122020017756B1
(pt)
*
|
2004-08-26 |
2022-02-15 |
Pfizer Inc |
Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
|
|
WO2006021885A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates
|
|
GT200600042A
(es)
*
|
2005-02-10 |
2006-09-27 |
Aventis Pharma Inc |
Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
|
|
JP2008535790A
(ja)
*
|
2005-03-03 |
2008-09-04 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
|
|
US20060258672A1
(en)
*
|
2005-05-13 |
2006-11-16 |
Joseph Barbosa |
Multicyclic compounds and methods of their use
|
|
US8088928B2
(en)
*
|
2005-08-04 |
2012-01-03 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
EP1910385B1
(en)
*
|
2005-08-04 |
2013-07-24 |
Sirtris Pharmaceuticals, Inc. |
Benzothiazoles and thiazolopyridines as sirtuin modulators
|
|
US8093401B2
(en)
*
|
2005-08-04 |
2012-01-10 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US7855289B2
(en)
*
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
HRP20130719T1
(en)
*
|
2005-08-24 |
2013-09-30 |
Eisai R&D Management Co., Ltd. |
Novel pyridine derivative and pyrimidine derivative (3)
|
|
DE602006018354D1
(de)
*
|
2005-12-05 |
2010-12-30 |
Pfizer Prod Inc |
Verfahren zur behandlung von abnormalem zellwachstum
|
|
KR101146852B1
(ko)
*
|
2005-12-05 |
2012-05-16 |
화이자 프로덕츠 인크. |
Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
|
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
|
BRPI0708615A2
(pt)
|
2006-03-07 |
2011-06-07 |
Array Biopharma Inc |
compostos de pirazol heterobicìclicos e métodos de uso
|
|
ES2336625T3
(es)
*
|
2006-03-22 |
2010-04-14 |
Vertex Pharmaceuticals Incorporated |
Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
|
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
|
EP2450437B1
(en)
|
2006-04-14 |
2017-05-17 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
|
US7601716B2
(en)
|
2006-05-01 |
2009-10-13 |
Cephalon, Inc. |
Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
|
|
US20080045589A1
(en)
*
|
2006-05-26 |
2008-02-21 |
Susan Kelley |
Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
|
|
JP2009539878A
(ja)
*
|
2006-06-08 |
2009-11-19 |
アレイ バイオファーマ、インコーポレイテッド |
キノリン化合物および使用方法
|
|
US7683060B2
(en)
|
2006-08-07 |
2010-03-23 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
CA2661333C
(en)
|
2006-08-23 |
2014-08-05 |
Eisai R&D Management Co., Ltd. |
Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
|
|
US7790885B2
(en)
*
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
|
WO2008042867A2
(en)
*
|
2006-09-29 |
2008-04-10 |
Emiliem Inc. |
Modulators of multiple kinases
|
|
CN101535276B
(zh)
|
2006-10-23 |
2013-08-28 |
赛福伦公司 |
作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物
|
|
GB0621607D0
(en)
*
|
2006-10-31 |
2006-12-06 |
Chroma Therapeutics Ltd |
Inhibitors of c-Met
|
|
ME02372B
(me)
|
2006-11-22 |
2016-06-20 |
Incyte Holdings Corp |
Imidazotriazini i imidazopiramidini kao inhibitori kinaze
|
|
ES2396160T3
(es)
|
2006-12-14 |
2013-02-19 |
Bayer Intellectual Property Gmbh |
Derivados de DIHIDROPIRIDINA que utiliza como inhibidores de la proteina quinasa
|
|
JPWO2008087736A1
(ja)
*
|
2007-01-19 |
2010-05-06 |
宇部興産株式会社 |
アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
|
|
WO2008088881A1
(en)
|
2007-01-19 |
2008-07-24 |
Xcovery, Inc. |
Kinase inhibitor compounds
|
|
CA2683559C
(en)
|
2007-04-13 |
2019-09-24 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
|
MX2009011210A
(es)
*
|
2007-04-16 |
2009-10-30 |
Abbott Lab |
Inhibidores de mcl1 de indol 7-no sustituido.
|
|
US8263585B2
(en)
|
2007-05-04 |
2012-09-11 |
Novartis Ag |
Organic compounds
|
|
TW200916472A
(en)
*
|
2007-06-20 |
2009-04-16 |
Sirtris Pharmaceuticals Inc |
Sirtuin modulating compounds
|
|
JP2010533729A
(ja)
|
2007-07-17 |
2010-10-28 |
プレキシコン，インコーポレーテッド |
キナーゼ調節のための化合物と方法、及びそのための適応
|
|
ES2394126T3
(es)
*
|
2007-07-26 |
2013-01-22 |
Novartis Ag |
Derivados de pirimidina útiles para el tratamiento de estados inflamatorios o alérgicos
|
|
KR101586503B1
(ko)
|
2007-09-13 |
2016-01-18 |
코덱시스, 인코포레이티드 |
아세토페논의 환원을 위한 케토리덕타제 폴리펩티드
|
|
WO2009055289A2
(en)
*
|
2007-10-23 |
2009-04-30 |
Allergan, Inc. |
Therapeutic substituted lactams
|
|
JP2011502984A
(ja)
*
|
2007-11-01 |
2011-01-27 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
サーチュインモジュレーターとしてのアミド誘導体
|
|
CA2705138A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Sirtris Pharmaceuticals, Inc. |
Solubilized thiazolopyridines
|
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
|
WO2009073224A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Ambit Biosciences Corp. |
Methods of treating certain diseases using pyrimidine derivatives
|
|
JP2009203226A
(ja)
*
|
2008-01-31 |
2009-09-10 |
Eisai R & D Management Co Ltd |
ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤
|
|
JPWO2009096198A1
(ja)
*
|
2008-02-01 |
2011-05-26 |
一般社団法人ファルマＩｐ |
新規ビアリール誘導体
|
|
WO2009099982A1
(en)
*
|
2008-02-04 |
2009-08-13 |
Osi Pharmaceuticals, Inc. |
2-aminopyridine kinase inhibitors
|
|
AR070317A1
(es)
*
|
2008-02-06 |
2010-03-31 |
Osi Pharm Inc |
Furo (3,2-c) piridina y tieno (3,2-c) piridinas
|
|
US20100311972A1
(en)
*
|
2008-02-18 |
2010-12-09 |
Mitsuo Nagai |
Method for producing phenoxypyridine derivative
|
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
|
US8268834B2
(en)
*
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
FR2928922B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
|
|
FR2928923B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
|
|
FR2928924B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
|
|
WO2009151800A1
(en)
*
|
2008-05-07 |
2009-12-17 |
Merck & Co., Inc. |
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
|
WO2009143211A2
(en)
|
2008-05-21 |
2009-11-26 |
Incyte Corporation |
Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
|
ES2670665T3
(es)
*
|
2008-06-19 |
2018-05-31 |
Xcovery Holding Company Llc |
Compuestos de piridazina carboxamida sustituidos como compuestos inhibidores de quinasa
|
|
AR073231A1
(es)
*
|
2008-08-29 |
2010-10-20 |
Genentech Inc |
Metodos diagnosticos y tratamientos para los tumores independientes del vegf (factor de crecimiento endotelial vascular)
|
|
WO2010046780A2
(en)
*
|
2008-10-22 |
2010-04-29 |
Institut Pasteur Korea |
Anti viral compounds
|
|
AT507187B1
(de)
|
2008-10-23 |
2010-03-15 |
Helmut Dr Buchberger |
Inhalator
|
|
JP2012509342A
(ja)
*
|
2008-11-20 |
2012-04-19 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
|
|
WO2010077624A1
(en)
*
|
2008-12-09 |
2010-07-08 |
Merck Sharp & Dohme Corp. |
Biaryl carboxamides
|
|
EP2376502B1
(en)
|
2008-12-19 |
2015-06-17 |
GlaxoSmithKline LLC |
Thiazolopyridine sirtuin modulating compounds
|
|
ES2663222T3
(es)
|
2008-12-19 |
2018-04-11 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina útiles como inhibidores de la quinasa ATR
|
|
JP2012102018A
(ja)
*
|
2009-03-03 |
2012-05-31 |
Astellas Pharma Inc |
アミド化合物
|
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
|
DE102009056886A1
(de)
|
2009-12-03 |
2011-06-09 |
Bayer Schering Pharma Aktiengesellschaft |
cMet-Inhibitoren zur Behandlung der Endometriose
|
|
EA025304B1
(ru)
|
2010-02-03 |
2016-12-30 |
Инсайт Холдингс Корпорейшн |
ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
|
|
EP2566858A2
(en)
*
|
2010-05-04 |
2013-03-13 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
|
JP2013526540A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
US9630956B2
(en)
|
2010-05-12 |
2017-04-25 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2013529200A
(ja)
*
|
2010-05-12 |
2013-07-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
WO2011143646A1
(en)
|
2010-05-14 |
2011-11-17 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
US10010439B2
(en)
|
2010-06-13 |
2018-07-03 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
|
US8628554B2
(en)
|
2010-06-13 |
2014-01-14 |
Virender K. Sharma |
Intragastric device for treating obesity
|
|
US9526648B2
(en)
|
2010-06-13 |
2016-12-27 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
|
US10420665B2
(en)
|
2010-06-13 |
2019-09-24 |
W. L. Gore & Associates, Inc. |
Intragastric device for treating obesity
|
|
WO2011162343A1
(ja)
|
2010-06-25 |
2011-12-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
|
|
JP2013531687A
(ja)
|
2010-07-16 |
2013-08-08 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ナトリウムチャネル遮断剤としてのピリジン化合物
|
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
|
EA024809B1
(ru)
|
2010-10-08 |
2016-10-31 |
Икскавери Холдинг Кампани, Ллс |
Замещенные соединения пиридазинкарбоксамида
|
|
US9133224B2
(en)
|
2010-11-29 |
2015-09-15 |
OSI Pharmaceuticals, LLC |
Macrocyclic kinase inhibitors
|
|
GB201021103D0
(en)
|
2010-12-13 |
2011-01-26 |
Univ Leuven Kath |
New compounds for the treatment of neurodegenerative diseases
|
|
EP2672847B1
(de)
|
2011-02-11 |
2015-04-22 |
Batmark Limited |
Inhalatorkomponente
|
|
MX2013009551A
(es)
*
|
2011-02-24 |
2013-09-06 |
Jiangsu Hanson Pharmaceutical Co Ltd |
Compuestos que contienen fosforo como inhibidores de proteina cinasa.
|
|
US9145390B2
(en)
|
2011-03-03 |
2015-09-29 |
Concert Pharmaceuticals, Inc. |
Derivatives of pyrazole-substituted amino-heteroaryl compounds
|
|
JO3363B1
(ar)
*
|
2011-04-13 |
2019-03-13 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
EP2707373A1
(de)
|
2011-05-10 |
2014-03-19 |
Bayer Intellectual Property GmbH |
Bicyclische (thio)carbonylamidine
|
|
EP2710003A1
(en)
|
2011-05-16 |
2014-03-26 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2739617A4
(en)
*
|
2011-07-27 |
2015-01-28 |
Nanjing Allgen Pharma Co Ltd |
SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS
|
|
AU2012291744A1
(en)
|
2011-08-02 |
2014-02-20 |
Pfizer Inc. |
Crizotinib for use in the treatment of cancer
|
|
SG10201606774UA
(en)
|
2011-09-30 |
2016-10-28 |
Vertex Pharma |
Processes for making compounds useful as inhibitors of atr kinase
|
|
WO2013049859A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
|
|
HUE034118T2
(en)
|
2012-03-06 |
2018-01-29 |
Pfizer |
Macrocyclic derivatives for the treatment of proliferative diseases
|
|
WO2013136170A1
(en)
|
2012-03-16 |
2013-09-19 |
Purdue Pharma L.P. |
Substituted pyridines as sodium channel blockers
|
|
CA2869309C
(en)
|
2012-04-05 |
2021-02-09 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase and combination therapies thereof
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
SG10201912111TA
(en)
|
2012-04-13 |
2020-02-27 |
Epizyme Inc |
Combination therapy for treating cancer
|
|
CN103387535B
(zh)
*
|
2012-05-10 |
2016-06-01 |
广东东阳光药业有限公司 |
取代的炔基吡啶化合物及其使用方法和用途
|
|
WO2013177092A1
(en)
*
|
2012-05-23 |
2013-11-28 |
Sunshine Lake Pharma Co., Ltd. |
Substituted alkynyl pyridine compounds and methods of use
|
|
JP6280546B2
(ja)
|
2012-06-26 |
2018-02-14 |
デル マー ファーマシューティカルズ |
ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
|
|
GB201211310D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Chroma Therapeutics Ltd |
CSF-1R kinase inhibitors
|
|
CN104603620B
(zh)
|
2012-09-24 |
2018-02-23 |
文塔纳医疗系统公司 |
使用间变性淋巴瘤激酶(alk)作为标志物鉴定治疗响应性非小细胞肺癌的方法
|
|
US8999632B2
(en)
|
2012-10-04 |
2015-04-07 |
Vertex Pharmaceuticals Incorporated |
Method for measuring ATR inhibition mediated increases in DNA damage
|
|
WO2014081816A1
(en)
*
|
2012-11-21 |
2014-05-30 |
Concert Pharmaceuticals, Inc. |
Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
|
|
SI2941432T1
(en)
|
2012-12-07 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
|
|
WO2014096941A1
(en)
|
2012-12-20 |
2014-06-26 |
Purdue Pharma L.P. |
Cyclic sulfonamides as sodium channel blockers
|
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
AU2014211856C1
(en)
*
|
2013-02-02 |
2018-04-12 |
Centaurus Biopharma Co., Ltd. |
Substituted 2-aminopyridine protein kinase inhibitor
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
EP2983674A4
(en)
|
2013-04-08 |
2017-05-10 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
EP2997377B1
(en)
|
2013-05-14 |
2018-07-18 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
WO2015034729A1
(en)
*
|
2013-09-05 |
2015-03-12 |
Calitor Sciences, Llc |
Substituted pyridine compounds and methods of use
|
|
WO2015036898A2
(en)
*
|
2013-09-10 |
2015-03-19 |
Shilpa Medicare Limited |
Novel salts of crizotinib and their preparation
|
|
RU2550346C2
(ru)
|
2013-09-26 |
2015-05-10 |
Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" |
Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
|
|
DK3053923T3
(en)
|
2013-09-30 |
2018-07-23 |
Korea Res Inst Chemical Tech |
TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS
|
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
DK3077397T3
(da)
|
2013-12-06 |
2019-12-16 |
Vertex Pharma |
2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
|
|
AU2014368945C1
(en)
|
2013-12-20 |
2019-05-16 |
Sagimet Biosciences Inc. |
Heterocyclic modulators of lipid synthesis and combinations thereof
|
|
CN103755627B
(zh)
*
|
2014-01-09 |
2016-02-17 |
定陶县友帮化工有限公司 |
2-氨基-3-羟基-5-氯吡啶的合成方法
|
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
US10730866B2
(en)
|
2014-04-07 |
2020-08-04 |
Purdue Pharma L.P. |
Indole derivatives and use thereof
|
|
WO2015167825A1
(en)
|
2014-04-29 |
2015-11-05 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
|
WO2015172747A1
(en)
*
|
2014-05-16 |
2015-11-19 |
Zhaoyin Wang |
Spirocyclic molecules as mth1 inhibitors
|
|
PL3152212T3
(pl)
|
2014-06-05 |
2020-06-15 |
Vertex Pharmaceuticals Inc. |
Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
|
|
LT3157566T
(lt)
|
2014-06-17 |
2019-08-12 |
Vertex Pharmaceuticals Incorporated |
Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
|
|
WO2016019909A1
(zh)
*
|
2014-08-07 |
2016-02-11 |
江苏豪森药业股份有限公司 |
一种抗癌化合物的新晶型及其制备方法和用途
|
|
WO2016028971A1
(en)
|
2014-08-21 |
2016-02-25 |
Bristol-Myers Squibb Company |
Tied-back benzamide derivatives as potent rock inhibitors
|
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
|
KR102569226B1
(ko)
|
2014-10-13 |
2023-08-22 |
아트린 파마슈티컬스 엘엘씨 |
운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제
|
|
GB2535427A
(en)
|
2014-11-07 |
2016-08-24 |
Nicoventures Holdings Ltd |
Solution
|
|
UY36391A
(es)
*
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
|
|
EP3215150B1
(en)
*
|
2014-11-07 |
2022-07-20 |
The Regents of The University of Michigan |
Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same
|
|
EP3227276B1
(en)
|
2014-12-02 |
2021-09-01 |
Ignyta, Inc. |
Combinations for the treatment of neuroblastoma
|
|
EP3246046A4
(en)
|
2015-01-13 |
2018-12-05 |
Kyoto University |
Agent for preventing and/or treating amyotrophic lateral sclerosis
|
|
AU2016224583B2
(en)
|
2015-02-25 |
2021-06-03 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
|
MA41598A
(fr)
*
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
KR20180011843A
(ko)
|
2015-06-11 |
2018-02-02 |
바실리어 파마슈티카 인터내셔널 리미티드 |
유출-펌프 억제제 및 이의 치료적 용도
|
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
|
US10405627B2
(en)
*
|
2015-07-14 |
2019-09-10 |
Michael Charles Boland, III |
Luggage with fold out table
|
|
JP6553726B2
(ja)
|
2015-08-20 |
2019-07-31 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
HK1258570A1
(zh)
|
2015-09-30 |
2019-11-15 |
Vertex Pharmaceuticals Inc. |
使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
|
|
GB2542838B
(en)
|
2015-10-01 |
2022-01-12 |
Nicoventures Trading Ltd |
Aerosol provision system
|
|
BR112018012255A2
(pt)
|
2015-12-18 |
2018-12-04 |
Ignyta Inc |
método para tratar câncer
|
|
WO2017161004A1
(en)
*
|
2016-03-15 |
2017-09-21 |
University Of South Florida |
PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
|
|
WO2017180723A1
(en)
|
2016-04-12 |
2017-10-19 |
Atrin Pharmaceuticals LLC |
Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
|
|
US10779980B2
(en)
|
2016-04-27 |
2020-09-22 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
|
EP3463355B1
(en)
*
|
2016-05-26 |
2024-08-28 |
Sonic Master Limited |
Modulators of dux4 for regulation of muscle function
|
|
TWI646094B
(zh)
|
2016-06-01 |
2019-01-01 |
大陸商貝達藥業股份有限公司 |
Crystal form of inhibitory protein kinase active compound and application thereof
|
|
EP3558992A4
(en)
|
2016-12-15 |
2020-12-02 |
ONO Pharmaceutical Co., Ltd. |
TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK)
|
|
CN106866627B
(zh)
*
|
2017-01-24 |
2021-09-14 |
南方医科大学 |
3-(1-(氨基吡啶氧基)乙基)苯甲酰胺衍生物及其合成方法和应用
|
|
JP6581320B2
(ja)
|
2017-02-08 |
2019-09-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
EP3624800A4
(en)
|
2017-05-16 |
2021-02-17 |
Eisai R&D Management Co., Ltd. |
TREATMENT OF HEPATOCELLULAR CARCINOMA
|
|
EP3654982A4
(en)
|
2017-07-18 |
2021-04-14 |
Nuvation Bio Inc. |
1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
|
|
WO2019018584A1
(en)
|
2017-07-18 |
2019-01-24 |
GiraFpharma LLC |
HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
|
|
AU2018302170B2
(en)
|
2017-07-19 |
2024-02-29 |
Ignyta, Inc. |
Pharmaceutical compositions comprising entrectinib
|
|
CN111225662B
(zh)
|
2017-10-17 |
2022-11-22 |
伊尼塔公司 |
药物组合物和剂型
|
|
CN107794282B
(zh)
*
|
2017-11-20 |
2020-12-25 |
浙江工业大学 |
一种克唑替尼手性中间体的制备方法及菌株
|
|
WO2019154665A1
(en)
*
|
2018-02-07 |
2019-08-15 |
Basf Se |
New pyridine carboxamides
|
|
JP7034512B2
(ja)
|
2018-03-15 |
2022-03-14 |
フーチェン ハイシィ ファーマシューティカルズ シーオー．，エルティーディー |
キナーゼ阻害剤としてのヘテロアリール化合物
|
|
CN110372664A
(zh)
*
|
2018-04-13 |
2019-10-25 |
华东理工大学 |
选择性jak2抑制剂及其应用
|
|
CN110396087A
(zh)
*
|
2018-04-25 |
2019-11-01 |
珠海宇繁生物科技有限责任公司 |
Hpk1激酶抑制剂、制备方法及其应用
|
|
WO2019206049A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Zhuhai Yufan Biotechnologies Co., Ltd |
Hpk1 inhibitors, preparation method and application thereof
|
|
CN108947895B
(zh)
*
|
2018-08-22 |
2021-09-24 |
肇庆中彩机电技术研发有限公司 |
一种抗癌活性的化合物
|
|
JP2022517418A
(ja)
*
|
2019-01-18 |
2022-03-08 |
ニューベイション・バイオ・インコーポレイテッド |
アデノシンアンタゴニストとしてのヘテロ環式化合物
|
|
EP3911323A4
(en)
|
2019-01-18 |
2022-11-16 |
Nuvation Bio Inc. |
HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
|
|
EP3911324A4
(en)
|
2019-01-18 |
2022-08-17 |
Nuvation Bio Inc. |
1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
|
|
EP4628487A3
(en)
|
2019-03-20 |
2025-12-24 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, and uses related thereto
|
|
KR20220004206A
(ko)
|
2019-05-14 |
2022-01-11 |
텔리진 엘티디. |
키네이스 억제제로 유용한 치환된 거대고리화합물
|
|
EP4725489A2
(en)
|
2019-08-02 |
2026-04-15 |
OneHealthCompany, Inc. |
Treatment of canine cancers
|
|
KR102426921B1
(ko)
*
|
2019-09-24 |
2022-07-29 |
주식회사 이노보테라퓨틱스 |
헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
CN112552293A
(zh)
*
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
KR102344185B1
(ko)
*
|
2020-02-26 |
2021-12-27 |
계명대학교 산학협력단 |
신규한 Pim 키나아제 억제제 및 이의 용도
|
|
CN113493437B
(zh)
*
|
2020-04-03 |
2022-07-26 |
中国药科大学 |
含苯并咪唑结构的化合物及其制备方法和用途
|
|
WO2021196655A1
(zh)
*
|
2020-04-03 |
2021-10-07 |
中国药科大学 |
含苯并咪唑结构的化合物及其制备方法与用途
|
|
EP4433445A4
(en)
*
|
2021-11-15 |
2026-04-01 |
Broad Inst Inc |
COMPOUNDS, COMPOSITIONS AND METHODS FOR INDUCING INTRACELLULAR ANTIMICROBIAL ACTIVITY AND FOR PREVENTING AND TREATMENT OF MICROBIAL INFECTIONS
|
|
IL317839A
(en)
|
2022-07-04 |
2025-02-01 |
Chugai Pharmaceutical Co Ltd |
Combination drug
|
|
CA3262258A1
(en)
|
2022-08-30 |
2025-06-12 |
Chugai Seiyaku Kabushiki Kaisha |
ASSOCIATION MEDICINE
|
|
WO2026071043A1
(en)
*
|
2024-09-30 |
2026-04-02 |
Alivexis, Inc. |
Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof
|